Cellular and Molecular Toxicology Core
细胞和分子毒理学核心
基本信息
- 批准号:10487473
- 负责人:
- 金额:$ 25.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-24 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse effectsAnalytical ChemistryAnimalsAntineoplastic AgentsApoptosisApplications GrantsArkansasAutophagocytosisBiologicalBiological AssayBiomedical ResearchBloodBone MarrowCancer PatientCancer SurvivorCellsCenters of Research ExcellenceChemicalsChemotherapy and/or radiationCollaborationsColorimetryComet AssayCommunicationCommunitiesComplexConsultationsCore FacilityCountryDNADNA DamageDNA FragmentationDNA NucleotidylexotransferaseDNA RepairData AnalysesDeoxyribonucleasesDevelopmentDiagnostic EquipmentDisease-Free SurvivalDoctor of PhilosophyEconomicsEnsureEnzyme-Linked Immunosorbent AssayEquipmentExperimental DesignsFacultyFee-for-Service PlansFees and ChargesFinancial HardshipFluorescence MicroscopyGoalsGovernmentHealthcareHeartHuman ResourcesImmune responseImmunohistochemistryIn Situ HybridizationIn Situ Nick-End LabelingIn VitroIndividualInjuryInstitutionInterventionIntestinesIonizing radiationKidneyLabelLaboratoriesLaboratory AnimalsLeadLeadershipLengthLiquid substanceLiverLong-Term EffectsLungMeasurementMeasuresMedicalMentorsMethodsMolecularMolecular AnalysisMolecular ToxicologyNatureNormal tissue morphologyOrganOutcomePerformancePharmaceutical PreparationsPhasePilot ProjectsPoisonPreparationProductivityPublicationsQuality of lifeRadiation Dose UnitRadiation therapyRegimenResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResourcesRiskSamplingScienceServicesSpectral KaryotypingSpleenTalentsTechniquesTestingTissuesToxic effectToxicologyToxinTrainingTreatment-Related CancerUniversitiesWorkanticancer researchassay developmentbaseburden of illnesscancer therapycell injurycostdesigndiagnostic signatureenzyme activityexperienceexposure routegenotoxicityin vivoinflammatory markerinnovationinstrumentinstrumentationmass spectrometermembernew technologynovelpreventprogramsradiation-induced tissue damageresponseside effectsmall moleculetherapy designtissue injurytoxicanttraining project
项目摘要
PROJECT SUMMARY/ABSTRACT
To elucidate the underlying cellular and molecular mechanisms of normal-tissue injury induced by anticancer
drugs or ionizing radiation, 4 highly innovative research projects developed by the talented young investigators
of the proposed Phase 2 COBRE Center for Studies of Host Response to Cancer Therapy at the University of
Arkansas for Medical Sciences (UAMS). These studies contribute to the development of novel mechanism-based
interventions to prevent or mitigate the side effects of chemo- and/or radiotherapy. To accomplish the goals of
their projects, these investigators will analyze various tissues at the cellular and molecular levels (in vitro and in
vivo) to determine potential injury. Due to the nature of the chemical and/or physical agent, route of exposure,
and the composition of the tissue, the response to the insult is complex and varies widely. This analysis requires
expensive and sophisticated instrumentation that individual laboratories cannot afford. To provide junior
investigators with state-of-the-art equipment, facilities, and consultation that would otherwise be prohibitive, the
Cellular and Molecular Toxicology Core (Core B) was established during Phase 1. In Phase 2, Core B will
continue to offer services under the leadership of Alexei G. Basnakian, MD, PhD, DSc, a well-established expert
in normal-tissue injury and cancer research fields, an experienced core facility director, and a successful COBRE
mentor. The core director will oversee well-trained technical personnel. During Phase 1, the core demonstrated
high productivity, and while offering services to project leaders and pilot project grantees at no cost, fees charged
to other users have made this core largely self-sufficient. The core provides project leaders with various basic
and advanced cellular and molecular analyses for chemotherapy- and radiation-induced tissue injury, particularly
irreversible cell injury associated with DNA fragmentation. In addition, the core will constantly expand the
repertoire of available techniques to meet the growing needs of the innovative research conducted by members
of the COBRE Center, as well as other investigators at UAMS. Specifically, the core will pursue the following
specific aims: provide sensitive and quantitative analysis of in vitro and in vivo functional and structural toxicity
(including genotoxicity) and measurements of drug and toxin concentrations (Aim 1); provide mentoring, training,
consultation, and technical assistance concerning experimental design, sample preparation, assay development,
data analysis, and preparation of high-quality figures for publications and grant applications as they relate to
cellular and molecular analysis of tissue injury (Aim 2); and identify and develop new technologies to assist in
the cutting-edge research of the Center (Aim 3). These objectives will greatly benefit the research proposed in
all 4 projects of the Phase 2 COBRE Center as well as enrich the research infrastructure of the institution.
项目摘要/摘要
阐明抗癌药物诱导正常组织损伤的细胞和分子机制,
药物或电离辐射,由才华横溢的年轻研究人员开发的4个高度创新的研究项目
在华盛顿大学的COBRE中心,研究宿主对癌症治疗的反应。
阿肯色州医学科学(UAMS)。这些研究有助于开发新的机制为基础的
预防或减轻化疗和/或放疗副作用的干预措施。为了实现
这些研究人员将在细胞和分子水平上分析各种组织(体外和体内)。
体内)以确定潜在损伤。由于化学和/或物理制剂的性质、接触途径,
和组织的组成,对损伤的反应是复杂的,变化很大。这一分析要求
昂贵和复杂的仪器,个别实验室负担不起。为了给年轻人提供
调查人员拥有最先进的设备,设施和咨询,否则将是禁止的,
在第1阶段期间建立了细胞和分子毒理学核心(核心B)。在第2阶段,核心B将
继续在Alexei G. Basnakian,MD,PhD,DSc,知名专家
在正常组织损伤和癌症研究领域,一个经验丰富的核心设施主任,和一个成功的COBRE
导师核心主任将监督训练有素的技术人员。在第一阶段,核心证明了
高生产力,同时免费向项目领导人和试点项目受赠人提供服务,
使这个核心在很大程度上自给自足。核心为项目负责人提供各种基本的
和先进的细胞和分子分析化疗和放射诱导的组织损伤,特别是
与DNA断裂相关的不可逆细胞损伤。此外,核心将不断扩大,
现有技术的全部,以满足成员进行的创新研究日益增长的需求
以及UAMS的其他研究人员。具体而言,核心将追求以下目标
具体目标:提供体外和体内功能和结构毒性的灵敏和定量分析
(包括遗传毒性)和测量药物和毒素浓度(目标1);提供指导、培训、
咨询和技术援助,涉及实验设计、样品制备、分析开发,
数据分析,并为出版物和赠款申请准备高质量的数字,因为它们与
组织损伤的细胞和分子分析(目标2);并确定和开发新技术,
中心的前沿研究(目标3)。这些目标将极大地有益于
COBRE中心二期的所有4个项目,并丰富了该机构的研究基础设施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexei G Basnakian其他文献
Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase δ, PCNA, RFC and RPA
- DOI:
10.1186/1471-2180-9-79 - 发表时间:
2009-04-23 - 期刊:
- 影响因子:4.200
- 作者:
Bum Yong Kang;Hong You;Sarmistha Bandyopadhyay;Nalini Agrawal;Russell B Melchert;Alexei G Basnakian;Yong Liu;Paul L Hermonat - 通讯作者:
Paul L Hermonat
Alexei G Basnakian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexei G Basnakian', 18)}}的其他基金
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10589265 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis
DNase 靶向缓解横纹肌溶解引起的急性肾损伤
- 批准号:
10292439 - 财政年份:2014
- 资助金额:
$ 25.28万 - 项目类别:
New mechanistic therapies for myoglobinuric acute kidney injury
肌红蛋白尿性急性肾损伤的新机制疗法
- 批准号:
9037502 - 财政年份:2014
- 资助金额:
$ 25.28万 - 项目类别:
New mechanistic therapies for myoglobinuric acute kidney injury
肌红蛋白尿性急性肾损伤的新机制疗法
- 批准号:
8821210 - 财政年份:2014
- 资助金额:
$ 25.28万 - 项目类别:
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis
DNase 靶向缓解横纹肌溶解引起的急性肾损伤
- 批准号:
10043820 - 财政年份:2014
- 资助金额:
$ 25.28万 - 项目类别:
DNase-Targeted Mitigation of Acute Kidney Injury Due to Rhabdomyolysis
DNase 靶向缓解横纹肌溶解引起的急性肾损伤
- 批准号:
10516029 - 财政年份:2014
- 资助金额:
$ 25.28万 - 项目类别:
Novel endonuclease-targeted approaches to nephroprotection
新型核酸内切酶靶向肾保护方法
- 批准号:
8391580 - 财政年份:2009
- 资助金额:
$ 25.28万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 25.28万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 25.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 25.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 25.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 25.28万 - 项目类别:
Discovery Grants Program - Individual